T lymphocytes in patients with primary vasculitis: Expansion of CD8+ T cells with the propensity to activate polymorphonuclear neutrophils

Rheumatology

Volumn 47, Issue 5, 2008, Pages 609-616

  Iking Konert, C ^a   Vogl, T ^a   Prior, B ^b   Wagner, C ^c   Sander, O ^a   Bleck, E ^a   Ostendorf, B ^a   Schneider, M ^a   Andrassy, K ^b   Hansch G M ^b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c BG UNFALLKLINIK LUDWIGSHAFEN   (Germany)

Author keywords

ANCA; CD11b; CD28; CD8; Microscopic polyangiitis; PMN; T cells; Vasculitis; WG

Indexed keywords

CD11B ANTIGEN; CD28 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; ENZYME ANTIBODY; GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MYELOBLASTIN;

ANTIGEN EXPRESSION; ARTICLE; CD4 CD8 RATIO; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOFLUOROMETRY; CYTOKINE PRODUCTION; DISEASE COURSE; DISEASE SEVERITY; HUMAN; HUMAN CELL; IMMUNOPATHOGENESIS; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; LEUKOCYTE ACTIVATION; LYMPHOCYTE SUBPOPULATION; MICROSCOPIC POLYANGIITIS; PRIORITY JOURNAL; REMISSION; SUPERNATANT; T LYMPHOCYTE ACTIVATION; UPREGULATION; WEGENER GRANULOMATOSIS;

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTIGENS, CD11B; ANTIGENS, CD28; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELLS, CULTURED; HUMANS; IMMUNOPHENOTYPING; INTERFERON TYPE II; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MYELOBLASTIN; NEUTROPHIL ACTIVATION; NEUTROPHILS; VASCULITIS; WEGENER GRANULOMATOSIS;

EID: 42949091796     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ken028     Document Type: Article

References (63)

1. Falk RJ, Jennette JC. Are ANCA pathogenic - oh yes they are. J Am Soc Nephrol 2002;13:1977-9.
2. Abdel-Salam B, Iking-Konert C, Schneider M, Andrassy K, Hänsch GM. Auto-antibodies to human cytoplasmic antigens (ANCA) do not bind to polymorphonuclear neutrophils in whole blood. Kidney Int 2004;66:1009-17.
3. Harper L, Savage COS. Pathogenesis of ANCA-associated systemic vasculitis. J Pathol 2000;190:349-59.
4. Sarrat P, Sneller MC. Pathogenesis of Wegener's granulomatosis: Current concepts. Expert Rev Mol Med 2005;13:1-19.
5. Hänsch GM, Iking-Konert C, Andrassy K. The pathogenesis of ANCA-associated vasculitides: Old hypotheses and new insights. Clin Nephrol 2005;64:460-4.
6. Bosch X, Guilabert A, Font J. Antineutrophil cytoplasmic antibodies. Lancet 2006;368:404-18.
7. Falk R, Terrel R, Charles L, Jennette J. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in Vitro. Proc, Natl Acad Sci USA 1990;87:4115-9.
8. Charles LA, Caldas ML, Falk RJ, Terrell RS, Jennette JC. Antibodies against granule proteins activate neutrophils in vitro. J Leukoc Biol 1991;50:539-46.
9. Keogan MT, Esnault VLM, Green AJ, Lockwood CM, Brown DL. Activation of normal neutrophils by anti-neutrophil cytoplasm antibodies. Clin Exp Immunol 1992;90: 228-34.
10. Ralston D, Marsh C, Lowe M, Wewers M. Antineutrophil cytoplasmic antibodies induce monocyte IL-8 release. Role of surface proteinase-3, alpha1-antitrypsin, and Fcgamma receptors. J Clin Invest 1997;100:1416-24.
11. Hatter K, van Burck S, Bickenbach A et al. Anti-proteinase antibodies (c-ANCA) prime CD14-depedent leukocyte activation. J Leukoc Biol 2005;78:992-1000.
12. Brouwer E, Hultema MG, Mulder AHL et al. Neutrophil activation in vitro and in vivo in Wegener's granulomatosis. Kidney Int 1994;45:1120-31.
13. Csernok E, Ernst M, Schmitt W, Bainton DF, Gross WL. Activated neutrophils express proteinase 3 on their plasma membrane in vitro and in vivo. Clin Exp Immunol 1994;95:244-50.
14. Müllier-Kabold AC, Kallenberg CG, Tervaert JW. Leucocyte membrane expression of proteinase 3 correlates with disease activity in patients with Wegener's granulomatosis. Br J Rheumatol 1998;37:901-7.
15. Morcos M, Zimmermann F, Radsak M et al. Autoantibodies to polymorphonuclear neutrophil elastase do not inhibit but enhance elastase activity. Am J Kidney Dis 1998;31:978-85.
16. Haller H, Eichhom J, Pieper K, Göbel U, Luft F. Circulating leukocyte integrin expression in Wegener's granulomatosis. J Am Soc Nephrol 1996;7:40-8.
17. Müller-Kobold AC, Mesander G, Stegeman CA, Kallenberg CG, Tervaert JW. Are circulating neutrophils intravascularly activated in patients with anti-neutrophil cytoplasmic antiloody (ANCA)-associated vasulitides? Clin Exp Immunol 1998;114: 491-9.
18. Alcorta D, Barbes DA, Dooley M et al. Microarray expression analysis of systemic lupus erythematodes and ANCA vasculitis patient leukocytes revealed disease specific gene expression signatures. Kid Blood Press Res 2005;28:171.
19. Hänsch GM, Radsak M, Wagner C et al. Expression of major histocompatibility class II antigens on polymorphonuclear neutrophils in patients with Wegener's granulomatosis. Kidney Int 1999;55:1181-8.
20. Iking-Konert C, Vogt S, Radsak M, Wagner C, Hansch GM, Andrassy K. Polymorphonuclear neutrophils in Wegener's granulomatosis acquire characteristics of antigen presenting cells. Kidney Int 2001;60:2247-62.
21. Gosselin EJ, Wardwell K, Rigby WF, Guyre PM. Induction of MHG class II on human polymorphonuclear neutrophils by granulocyte/macrophage colony-stimulating factor, IFN-gamma, and IL-3. J Immunol 1993;151:1482-90.
22. Reinisch W, Tillinger W, Lichtenberger C et al. In vivo induction of HLA-DR on human neutrophils in patients treated with interferon-γ. Blood 1996;87:3068.
23. Radsak M, Iking-Konert C, Stegmaier 8, Andrassy K, Hänech GM. Polymorpho-nuclear neutrophils (PMN) as accessory cells for T-cell activation: MHC class II restricted antigen-dependent induction of T-cell proliferation. Immunology 2000;101:521-30.
24. Ellis TN, Beaman BL. Interferon-gamma activation of polymorphonuclear neutrophil function. Immunology 2004;112:2-12.
25. Gross WL, Csemok E, Helmchen U. Antineutrophil cytoplasmic autoantibodies, autoantigens, and systemic vasculitis. APMIS 1995;103:81-97.
26. Clayton AR, Savage CO. What you should know about PR3-ANCA. Evidence for the role of T cells in the pathogenesis of systemic vasculitis. Arthritis Res 2000;2:260-2.
27. Sanders JS, Stegeman CA, Kallenberg CG. The Th1 and Th2 paradigm in ANCA-associated vascultis. Kidney Blood Press Res 2003;26:215-20.
28. Lamprecht P. Off balance: T-cells in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides. Clin Exp Immunol 2005;141:201-10.
29. Schmitt WH, Hagen EC, Neumann I, Nowack R, Flores-Suarez LF, van der Woude FJ. European Vasculitis Study GroupTreatment of refractory Wegener's granulomatosis with antithymocyte globulin(ATG): An open study in 15 patients. Kidney Int 2004;65:1440-8.
30. Vogt S, Iking-Konert C, Hug F, Andrassy K, Hansch GM. Shortening of telomeres: Evidence for replicative senescence of T cells derived from patients with Wegener's granulomalosis. Kidney Int 2003;63:2144-51.
31. Zhou Y, Huang D, Paris PL, Sauter CS, Prock KA, Hoffman GS. An analysis of CTLA-4 and proinflammatory cytokine genes in Wegener's granulomatosis. Arthritis Rheum. 2004;50:2645-50.
32. Abdulahad WH, van der Geld YM, Stageman CA, Kallenberg CG. Persistent expansion of CD4+ effector memory T cells in Wegener's granulomatosis. Kidney Int 2006;70:938-47.
33. Wagner C, Hänsch M. Receptors for complement, C3 on T-lymphocytes: relics of evolution or functional molecules? Mol Immunol 2006;43:22-30.
34. McFarland HI, Nahill SR, Maciaszek JW, Welsh RM. CD11b (Mac-1): A marker for CD8+ cytotoxic T cell activation and memory in virus infection. J Immunol 1992;149:1326-33.
35. Christensen JE, Andreasen SO, Christensen JP, Thomson AR. CD11b expression as a marker to distinguish between recently activated effector CD8(+) T cells and memory cells. Int Immunol 2001;13:593-600.
36. Fiorentini S, Licenziati S, Alessandri G et al. CD11b expression identifies CD8+CD28+ T lymphocytes with phenotype and function of both naive/memory and effector cells. J Immunol 2001;166:900-7.
37. Luqmani R, Bacon P, Moots R et al. Birmingham vasculitis activity score (BVAS) in systemic necrotizing vasculitis. Q J Med 1994;87:671-8.
38. Jennette JC, Falk RJ, Andrassy K et al. Nomenclature of systemic vasculitis: The proposal of an international consensus conference. Arthritis Rheum 1994;37:187-92.
39. Leavitt RY, Fauci AS, Bloch DA et al. The American College of Rheumatology 1990 Criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 1990;33:1101-7.
40. Reinhold-Keller E, Kekow J, Schnabel A et al. Influence of disease manifestation and antineutrophil cytoplasmic antibody titer on the response to pulse cyclophosphamide therapy in patients with Wegener's granulomatosis. Arthritis Rheum 1994;37:919-24.
41. de Groot K, Gross WL, Herlyn K, Reinhold-Keller E. Development and validation of a disease extent index for Wegener's granulomatosis. Clin Nephrol 2001;55:31-8.
42. Schlesier M, Kasper T, Gutfleisch J, Wolff-Vorbeck G, Peter HH. Activated CD4+ and CD8+ T-cell subsets in Wegener's granulomatosis. Rheumatol Int 1995;145: 213-9.
43. Moosig F, Czemok E, Wang G, Gross WL. Costimulatory molecules in Wegner's granulomatosis (WG): Lack of expression of CD28 and preferential up-regulation of its ligands B7-1 (CD80) and B-2 (CD86) on T-cells. Clin Exp Immunol 1998;114: 113-8.
44. Marinaki S, Neumann I, Kalsch AI et al. Abnormalities of CD4T cell subpopulations in ANCA-associated vasculitis. Clin Exp Immunol 2005;140:181-9.
45. Porges A, Redecha P, Kimberly W et al. Anti-neutrophil cytoplasmic antibodies engage and activate human neutrophils, via Fc gamma RIIa. J Immunol 1994;153:1271-80.
46. Savill J. Apoptosis in resolution of inflammation. J Leukoc Biol 1997;61:375-80.
47. Savill J, Haslett C, Hellewell PG, Williams TJ. Fate of neutrophil. Immunopharmacology of neutrophils. San Diego: CA Academic, 1994;295-314.
48. Dallegri F, Ottonello L. Tissue injury in neutrophilic inflammation. InflammRes 1997;46:382-91.
49. Edwards SW, Moulding DA, Derouet R, Moots RJ. Regulation of neutrophil apoptosis. In: Cassatella M (eA.), The neutrophil: an emerging regulator of inflammatory and immune response. Chem Immunol Allergy 2003;83:204-24; Basel: Karger.
50. Hänsch GM, Wagner C. Expression of MHC class II antigen and coreceptor molecules in polymorphonuclear neutrophils. Chem Immunol Allergy 2003;83:45-63.
51. Giscombe R, Nityanand S, Lewin N, Grunewald J, Lefvert AK. Expanded T cell populations in patients with Wegener's granulomatosis: characteristics and correlates with disease activity. J Clin Immunol 1998;18:404-13.
52. Ludviksson BR, Sneller MC, Chua KS et al. Active Wegener's granulomatosis is associated with HLA-DR+ CD4+ T cells exhibiting an unbalanced Th1-type T cell cytokine pattern: Reversal with IL-10. J Immunol 1998;160:3602-9.
53. Komocsi A, Lamprecht P, Csernok E et al. Peripheral blood and granuloma CD4(+)CD28(-) T cells are a major source of interferon-gamma and tumor necrosis factor-alpha in Wegener's granulomatosis. Am J Pathol 2002;160:1717-24.
54. Spriewald BM, Witzke O, Wassmuth R et al. District tumour necrosis factor alpha, interferon gamma, interleukin 10, and cytotoxic T cell antigen 4 gene polymorphisms in disease occurrence and end stage renal disease in Wegener's granulomatosis. Ann Rheum Dis 2005;64:457-61.
55. Lamprecht P, Moosig F et al. CD28 negative T-cells are enriched in granulomatous lesions of the respiratory tract in Wegener's granulomatosis. Thorax 2001;56:751-7.
56. Lamprecht P, Bruhl H, Csernok E et al. Differences in CCR5 expression on peripheral blood CD4+CD28- T-cells and in granulomatous lesions between localized and generalized Wegener's granulomatosis. Clin Immunol 2003;108:1-7.
57. Brouwer E, Stegeman C, Huitema M et al. T cell reactivity to proteinase 3 and myeloperoxidase in patients with Wegener's granulomatosis (WG). Clin Exp Immunol 1994;98:448-53.
58. Pope ER, Franssen CF, Limburg PC, Huitema MG, Kallenberg CG, Tervaert JW. In vitro cytokine production and proliferation of T cells from patients with anti-proteinase 3- and antimyeloperoxidase-associated vasculitis, in response to proteinase 3 and myeloperoxidase. Arthritis Rheum 2002;46:1894-904.
59. van der Geld YM, Huitema MG, Franssen CF, van der Zee R, Limburg PC, Kallenberg CG. In vitro T lymphocyte responses to proteinase 3 (PR3) and linear peptides of PR3 in patients with Wegener's granulomatosis (WG). Clin Exp Immunol 2000;122:504-13.
60. Winek J, Mueller A, Csernok E, Gross WL. Lamprecht P. Frequency of proteinase 3 (PR3)-specific autoreactive T cells determined by cytokine flow cytometry in Wegener's granulomatosis. J Autoimmun 2004;22:79-85.
61. Wagner C, Hänsch GM, Stegmaier S, Denefleh B, Hug F, Schoels M. The complement receptor 3, CR3 (CD11b/CD18) on T lymphocytes: activation-dependent up-regulation and regulatory function. Eur J Immunol 2001;31:1173-80.
62. Vallejo AN. CD28 extinction in human T cells: Altered functions and the program of T-cell senescence. Immunol Rev 2005;205:158-69.
63. Fanger NA, Liu C, Guyre PM et al. Activation of human T cells by major histocompatability complex class II expressing neutrophils: proliferation in the presence of superantigen, but not tetanus toxoid. Blood 1997;89:4128-35.